Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11046044rdf:typepubmed:Citationlld:pubmed
pubmed-article:11046044lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C0033684lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C0021747lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C1415900lld:lifeskim
pubmed-article:11046044lifeskim:mentionsumls-concept:C1879547lld:lifeskim
pubmed-article:11046044pubmed:issue9lld:pubmed
pubmed-article:11046044pubmed:dateCreated2000-11-3lld:pubmed
pubmed-article:11046044pubmed:abstractTextThe cytoplasmic domain of the human type I IFN receptor chain 2 (IFNAR2c or IFN-alphaRbetaL) was used as bait in a yeast two-hybrid system to identify novel proteins interacting with this region of the receptor. We report here a specific interaction between the cytoplasmic domain of IFN-alphaRbetaL and a previously identified protein, RACK-1 (receptor for activated C kinase). Using GST fusion proteins encoding different regions of the cytoplasmic domain of IFN-alphaRbetaL, the minimum site for RACK-1 binding was mapped to aa 300-346. RACK-1 binding to IFN-alphaRbetaL did not require the first 91 aa of RACK-1, which includes two WD domains, WD1 and WD2. The interaction between RACK-1 and IFN-alphaRbetaL, but not the human IFN receptor chain 1 (IFNAR1 or IFN-alphaRalpha), was also detected in human Daudi cells by coimmunoprecipitation. RACK-1 was shown to be constitutively associated with IFN-alphaRbetaL, and this association was not effected by stimulation of Daudi cells with type I IFNs (IFN-beta1b). RACK-1 itself did not become tyrosine phosphorylated upon stimulation of Daudi cells with IFN-beta1b. However, stimulation of cells with either IFN-beta1b or PMA did result in an increase in detectable immunofluorescence and intracellular redistribution of RACK-1.lld:pubmed
pubmed-article:11046044pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:languageenglld:pubmed
pubmed-article:11046044pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11046044pubmed:statusMEDLINElld:pubmed
pubmed-article:11046044pubmed:monthNovlld:pubmed
pubmed-article:11046044pubmed:issn0022-1767lld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:CrozeEElld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:PerezH DHDlld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:ColamoniciOOlld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:MinshallR DRDlld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:AsarnowDDlld:pubmed
pubmed-article:11046044pubmed:authorpubmed-author:UsachevaAAlld:pubmed
pubmed-article:11046044pubmed:issnTypePrintlld:pubmed
pubmed-article:11046044pubmed:day1lld:pubmed
pubmed-article:11046044pubmed:volume165lld:pubmed
pubmed-article:11046044pubmed:ownerNLMlld:pubmed
pubmed-article:11046044pubmed:authorsCompleteYlld:pubmed
pubmed-article:11046044pubmed:pagination5127-32lld:pubmed
pubmed-article:11046044pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:meshHeadingpubmed-meshheading:11046044...lld:pubmed
pubmed-article:11046044pubmed:year2000lld:pubmed
pubmed-article:11046044pubmed:articleTitleReceptor for activated C-kinase (RACK-1), a WD motif-containing protein, specifically associates with the human type I IFN receptor.lld:pubmed
pubmed-article:11046044pubmed:affiliationDepartment of Immunology, Berlex Biosciences, Richmond CA 94804, USA. ed_croze@berlex.comlld:pubmed
pubmed-article:11046044pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11046044pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
entrez-gene:10399entrezgene:pubmedpubmed-article:11046044lld:entrezgene
entrez-gene:3455entrezgene:pubmedpubmed-article:11046044lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:11046044lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11046044lld:pubmed